Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (12340)	11/26/1999 2:07:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

You stated>>>>>>>>>Fda will accept reasonable hypothesis, will assure that ethical issues are met, safety is number 1, and efficacy must be establish.<<<<<< Then you agree that Phase III trauma was a reasonable hypothesis? You have to face the fact that your beloved FDA allowed Phase II results to go into Phase III. It is the job of your beloved FDA to prevent garbage from being put upon unsuspecting patients. You are TOTALLY wrong in saying that it is ONLY the company's responsibility. I would certainly hate to see what garbage some companies would try on unsuspecting patients IF not for your beloved FDA. So, once again, you can't have your soggy potato chips and eat them too. Please spare us the trials and tribulations of ANY money losing Biotech. Look at the history of Biogen and Amgen and you will see ALL is forgiven once product is put on the market. Now, what was the original indication for Epogen? LOL Hmmmmmm Will it matter what original indication was for Neuprex if approved? Cacaito, it is a shame.........you know better.